Last reviewed · How we verify
Twinrix for ATN 024
Twinrix for ATN 024 is a Biologic drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved. Also known as: There are no other names..
Twinrix is a vaccine used to prevent hepatitis B infection. It works as an antagonist by blocking the integrin alpha-5/beta-1 protein.
At a glance
| Generic name | Twinrix for ATN 024 |
|---|---|
| Also known as | There are no other names. |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Twinrix for ATN 024 CI brief — competitive landscape report
- Twinrix for ATN 024 updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI
Frequently asked questions about Twinrix for ATN 024
What is Twinrix for ATN 024?
Who makes Twinrix for ATN 024?
Is Twinrix for ATN 024 also known as anything else?
What development phase is Twinrix for ATN 024 in?
Related
- Manufacturer: University of North Carolina, Chapel Hill — full pipeline
- Also known as: There are no other names.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing